Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

site specific immunomodulator QBECO

A formulation composed of components of the inactivated bacteria Escherichia coli (E. coli), with potential immunomodulating activity. Upon subcutaneous administration, site specific immunomodulator (SSI) QBECO stimulates the innate immune system by recruiting and activating M1 macrophages. This may restore the unhealthy and altered gut microbiome, restore the function in the gastrointestinal (GI) tact, restore the immune system and rebuild normal barrier function. In addition, by enhancing and optimizing immune function, cancer cell proliferation may be inhibited and GI tract-related inflammatory diseases may be treated.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:E. coli-based formulation QBECO
SSI QBECO
Code name:QBECO
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search